Patient with stage IV melanoma with BRAF mutation — immunotherapy or BRAF and MEK inhibitors?
Abstract
Treatment of patients with non-operative or metastatic melanoma has changed. New therapies (immunotherapy, targeted therapies — BRAF/MEK inhibitors) significantly prolonged the survival of melanoma patients. The therapy sequence has not been determined, especially in the group of patients with BRAF mutation-positive melanoma. We present a case of a 44-year-old patient with BRAF mutation-positive metastatic. Due to the slow current course of the disease, normal LDH activity, lack of metastases to the central nervous system, it was decided to use nivolumab immunotherapy in the first line of treatment. After 24 weeks of treatment, a partial remission was observed. The treatment was without complications. Currently, the patient continues immunotherapy. Treatment with nivolumab in the described case proved to be effective. The decision about the choice of a particular procedure must be consistent with dynamic of cancer, the patient’s current condition and should always be discussed with the patient.
Keywords: melanomaimmunotherapytreatment linenivolumab
References
- Luke JJ, Flaherty KT, Ribas A, et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017; 14(8): 463–482.
- Chapman PB, Hauschild A, Robert C, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26): 2507–2516.
- Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380(9839): 358–365.
- Flaherty KT, Robert C, Hersey P, et al. METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012; 367(2): 107–114.
- Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367(18): 1694–1703.
- Ackerman A, Klein O, McDermott DF, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. 2014; 120(11): 1695–1701.
- Long GV, Weber JS, Infante JR, et al. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol. 2016; 34(8): 871–878.